US FDA discloses info on enforcement and compliance actions
This article was originally published in SRA
The US Food and Drug Administration has taken steps to disclose more information about its enforcement and compliance actions against companies in the pharmaceutical, medical device and other sectors1.
You may also be interested in...
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.